Board of Directors
MDxHealth was established by a management staff with extensive biotechnology industry experience.
Mr. Edward L. Erickson
Chairman of the Board, Independent Director
Mr. Erickson has extensive executive level experience in diagnostics, therapeutics, and life science research products having served as president, CEO or a director of over a dozen companies in these industries. He is currently President and CEO of Saladax Biomedical, Inc., a diagnostics company in the fields of companion diagnostics and therapeutic dose management.
Prior to joining Saladax, he served as President and CEO of BioNanomatrix, Inc., a privately held genomics company developing and commercializing proprietary DNA analysis systems. Previously, he was the Chairman, President and CEO of Cellatope Corporation, a private company developing diagnostic products in the field of autoimmune diseases. Prior to that, he served in top leadership roles, including president, CEO and/or chairman, of three venture-capital backed medical products companies, Cholestech, DepoTech and Immunicon, which successfully completed initial public offerings under his leadership. Earlier in his career, he held senior executive positions at The Ares-Serono Group and Amersham International. Mr. Erickson is currently a director of Metabolon and chairman of MDxHealth. He holds an MBA from the Harvard Graduate School of Business Administration and B.S. and M.S. degrees from the Illinois Institute of Technology. He did military service as an officer in the U.S. Navy’s nuclear submarine force.
Mr. Raphael Wisniewski
Director, representing Edmond de Rothschild Investment Partners
Mr. Raphael Wisniewski is a Partner at Edmond de Rothschild Investment Partners. Previously, Mr. Wisniewski was a Partner at Goldman Sachs Group and Salomon Smith Barney, Inc. and an Associate at Compagnie Générale de Santé.
He is a Director at Pamgene International BV, Poxel SA, Nautilus Biotech, and Novagali Pharma. Mr. Wisniewski holds a degree from HEC and a D.E.A. in Economics and Finance from IEP Paris.
Mrs.Ruth Devenyns
Independent Director
Mrs. Devenyns (1964), a Belgian national, is currently an investment director at KBC Private Equity.
She joined KBC Bank's Economic Research Department in 1986, where she covered several industries including the chemical & pharmaceutical industry. In 1992, she moved to the bank's Corporate Finance Department. In 1995, she was asked to start up KBC Securities' equity research team, where she gradually specialized in biotechnology. She was actively involved in a number of IPO's and private placements. Mrs. Devenyns holds a Master's degree in applied economics from Ghent University.
Dr. Jan Groen
CEO (Executive member of the Board)
Dr. Jan Groen joined MDxHealth in 2010 and has more than 25 years of experience in the clinical diagnostic industry, with a particular focus on emerging technologies, product development and commercialization.
Dr. Groen was previously the president of Agendia, Inc. and COO of Agendia B.V., responsible for their United States and European diagnostic operations, respectively. Prior to this, he served as VP of Research & Development at Focus Diagnostics, Inc., a subsidiary of Quest Diagnostics, in California. Dr. Groen has held numerous management and scientific positions at ViroClinics B.V., the Erasmus Medical Center, and Akzo-Nobel. Dr. Jan Groen is a supervisory board member of IBL International B.V. Dr. Groen holds a Ph.D. degree from the Erasmus University Rotterdam and published more than 125 papers in international scientific journals in the field of clinical diagnostics.
Mr. Rudi Mariën
Director, representing Biovest CVA
Mr. Rudi Mariën is the President and owner of Biovest CVA. Previously Mr. Mariën was the Vice President of Cerba European Lab and President and Managing Director of Gengest Bvba.
Mr. Rudi Mariën was co-founder, reference shareholder and Chairman of Innogenetics, and has been the founder, shareholder and Managing Director of several clinical reference laboratories. He was also the founder, shareholder and Managing Director of the Barc Group, a leading international centralized clinical laboratory, exclusively dedicated to pharmaceutical studies. Through his management company, Gengest BVBA, Mr Mariën has board mandates in different publicly listed and private biotech companies.
Mr. Mark Myslinski
Independent Director
Mr. Myslinski is currently CEO of Rapid Pathogen Screening, Inc. a leading global developer, manufacturer and marketer of rapid point-of-care diagnostic tests for infectious diseases, inflammatory conditions and exposure to biochemical warfare agents. Previously, Mr. Myslinski was CEO of RedPath Integrated Pathology, Inc.
Mr. Myslinski was also a Johnson & Johnson executive where his responsibilities included building a new, worldwide Evidence-Based Medicine function for the Ortho-Clinical Diagnostics unit. For five years, Mr. Myslinski was General Manager of Johnson & Johnson's Veridex, LLC, a division focused on molecular and cellular diagnostics that achieved rapid sales growth under Mr. Myslinski's tenure. Mr. Myslinski also held executive roles in the venture-backed start-ups Interscope Technologies and Precision Therapeutics, both focused on the field of pathology with an emphasis on cancer.
Dr. Karin Dorrepaal
Director
Dr. Dorrepaal was in 2011 on the Supervisory Board of Ergo Versicherungsgruppe and on the advisory committees of Triton Private Equity.
Dr. Karin Louise Dorrepaal received her Ph.D. in medicine from the Free University of Amsterdam and her MBA from the Erasmus University Rotterdam School of Management.
Until 2004, Dr. Dorrepaal was vice-president of Booz and Company, Management Consultants, where she specialized in the pharmaceutical industry and advised on issues regarding strategy, sales, marketing and supply chain.
From 2004 until 2006, Dr. Dorrepaal served on the executive board of Schering AG, where she was responsible for Schering’s Global Business Unit Diagnostic Imaging and Supply Chain and Procurement.